Research

2010-04-23-15-53-231-230x14

Current Studies

  • Scaling - Evaluation of methods to achieve 3D delivery on multiple output devices
  • Vergence/attention - Evaluation of the effect of convergence location on the salience of S3D content.
  • Effects of exposure to S3D on ‘expert viewers’ (Ongoing, testing began end of July 2010)
  • Effects of crosstalk on perceived depth from stereo and mono occlusions (study results presented at Stereoscopic Displays and Applications Conference 2011)
  • Perception of reversed stereo

As part of the key activities of the consortium York’s Centre for Vision Research and Future Cinema Lab have devised a cyclical process of S3D film creation and applied vision research that investigates issues such as:

•    estimating, measuring and compensating for the geometrical and perceptual effects of scaling from cinematic display to home theatre to desktop to mobile platforms, and

•    evaluating the link between viewer locus of attention and plane at which cameras are converged in 3D images.

Centre for Vision Research resident investigators also support and offer consultation for production and workflow to 3DFLIC partners, and to the industry at large, presenting their findings at symposia, workshops and other venues.

In addition, the Future Cinema Lab is conducting research into the history and theoretical framework of S3D cinema in Canada. A digital archive of publications is underway.

Hospira Submits New Biologics License Application to U

LAKE FOREST, Ill., Jan. Food and Drug Administration (FDA) for Retacrit a proposed biosimilar to Amgen’s EPOGEN (epoetin alfa) and Janssen’s PROCRIT (epoetin alfa).

The biosimilar application was submitted on Dec. 16, 2014, under the new 351(k) approval pathway created by the Biologics Price Competition and Innovation Act of 2009 cheap nfl jerseys from china (BPCIA). cheap nhl jerseys is proud to build upon our global experience of providing biosimilars to patients across the world.” Biosimilars are biologic drugs that are highly similar to a reference biopharmaceutical product and demonstrate no clinically meaningful differences in terms of the safety, purity and potency of the product. Biosimilars offer high quality, lower cost alternatives to reference biologics.

About Hospira BiosimilarsGlobally, Hospira has many years of experience in the field of biologics and has one of the largest biosimilar pipelines in the industry. is the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill.

Private Securities Litigation Reform Act of 1995 A Caution Concerning Forward Looking Statements

This press release contains, or may contain, forward looking statements within wholesale jerseys the meaning cheap jerseys of the Private Securities Litigation Reform Act of 1995. Hospira cautions that these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward looking statements. Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward looking statements as a result of subsequent events or developments, except as required by law.Articles Connexes: